Cargando…

Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review

INTRODUCTION: Primary dysmenorrhea (PD) was the most common gynecological disorder, with an increasingly high prevalence worldwide. PD often accompanied other dysmenorrhea-associated symptoms to trigger exacerbations, and even cause depression and anxiety for patients. As the effective first-line me...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhe, Peng, Yingying, Qiang, Xiaoyu, Song, Geliang, Yang, Fengwen, Pang, Bo, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586373/
https://www.ncbi.nlm.nih.gov/pubmed/36269706
http://dx.doi.org/10.1371/journal.pone.0276129
_version_ 1784813679074607104
author Chen, Zhe
Peng, Yingying
Qiang, Xiaoyu
Song, Geliang
Yang, Fengwen
Pang, Bo
Wang, Hui
author_facet Chen, Zhe
Peng, Yingying
Qiang, Xiaoyu
Song, Geliang
Yang, Fengwen
Pang, Bo
Wang, Hui
author_sort Chen, Zhe
collection PubMed
description INTRODUCTION: Primary dysmenorrhea (PD) was the most common gynecological disorder, with an increasingly high prevalence worldwide. PD often accompanied other dysmenorrhea-associated symptoms to trigger exacerbations, and even cause depression and anxiety for patients. As the effective first-line medication, non-steroidal anti-inflammatory drugs (NSAIDs) have become widespread across China and combined with oral traditional Chinese patent medicines (TCPMs) for PD in clinical practice. We hope to provide better efficacy and safety evidence about oral TCPMs combined with NSAIDs (oral TCPMs+NSAIDs) for patients with PD by this network meta-analysis. METHODS AND ANALYSIS: We will perform a Bayesian network meta-analysis of all oral TCPMs+NSAIDs for clinical diagnosis as PD. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, VIP information resource integration service platform databases, and clinical registers will be searched from the database inception to June 30, 2022 to find randomized controlled trials. Two reviewers will independently screen and check titles and abstracts and read the full text. Data extraction with the same criteria will be conducted by two researchers, including study characteristics, participant characteristics, interventions and comparators, and outcomes. We will perform the network meta-analysis by the Bayesian random method to analyze the direct and indirect comparisons. Meta-regression with multiple covariates will be conducted to find the potential heterogeneity. We will perform the sensitivity analysis to identify the potential effect on the robustness of our results. Evidence certainty of all interventions in outcomes will be identified and assessed by Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) assessment. Funnel plots with Egger test and Begg’s test to detect the potential publication bias. TRIAL REGISTRATION: PROSPERO registration number: CRD42021265675.
format Online
Article
Text
id pubmed-9586373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95863732022-10-22 Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review Chen, Zhe Peng, Yingying Qiang, Xiaoyu Song, Geliang Yang, Fengwen Pang, Bo Wang, Hui PLoS One Study Protocol INTRODUCTION: Primary dysmenorrhea (PD) was the most common gynecological disorder, with an increasingly high prevalence worldwide. PD often accompanied other dysmenorrhea-associated symptoms to trigger exacerbations, and even cause depression and anxiety for patients. As the effective first-line medication, non-steroidal anti-inflammatory drugs (NSAIDs) have become widespread across China and combined with oral traditional Chinese patent medicines (TCPMs) for PD in clinical practice. We hope to provide better efficacy and safety evidence about oral TCPMs combined with NSAIDs (oral TCPMs+NSAIDs) for patients with PD by this network meta-analysis. METHODS AND ANALYSIS: We will perform a Bayesian network meta-analysis of all oral TCPMs+NSAIDs for clinical diagnosis as PD. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, VIP information resource integration service platform databases, and clinical registers will be searched from the database inception to June 30, 2022 to find randomized controlled trials. Two reviewers will independently screen and check titles and abstracts and read the full text. Data extraction with the same criteria will be conducted by two researchers, including study characteristics, participant characteristics, interventions and comparators, and outcomes. We will perform the network meta-analysis by the Bayesian random method to analyze the direct and indirect comparisons. Meta-regression with multiple covariates will be conducted to find the potential heterogeneity. We will perform the sensitivity analysis to identify the potential effect on the robustness of our results. Evidence certainty of all interventions in outcomes will be identified and assessed by Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) assessment. Funnel plots with Egger test and Begg’s test to detect the potential publication bias. TRIAL REGISTRATION: PROSPERO registration number: CRD42021265675. Public Library of Science 2022-10-21 /pmc/articles/PMC9586373/ /pubmed/36269706 http://dx.doi.org/10.1371/journal.pone.0276129 Text en © 2022 Chen et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Study Protocol
Chen, Zhe
Peng, Yingying
Qiang, Xiaoyu
Song, Geliang
Yang, Fengwen
Pang, Bo
Wang, Hui
Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review
title Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review
title_full Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review
title_fullStr Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review
title_full_unstemmed Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review
title_short Oral traditional Chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: A protocol for Bayesian network meta-analysis and systematic review
title_sort oral traditional chinese patent medicines combined with non-steroidal anti-inflammatory drugs for primary dysmenorrhea: a protocol for bayesian network meta-analysis and systematic review
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586373/
https://www.ncbi.nlm.nih.gov/pubmed/36269706
http://dx.doi.org/10.1371/journal.pone.0276129
work_keys_str_mv AT chenzhe oraltraditionalchinesepatentmedicinescombinedwithnonsteroidalantiinflammatorydrugsforprimarydysmenorrheaaprotocolforbayesiannetworkmetaanalysisandsystematicreview
AT pengyingying oraltraditionalchinesepatentmedicinescombinedwithnonsteroidalantiinflammatorydrugsforprimarydysmenorrheaaprotocolforbayesiannetworkmetaanalysisandsystematicreview
AT qiangxiaoyu oraltraditionalchinesepatentmedicinescombinedwithnonsteroidalantiinflammatorydrugsforprimarydysmenorrheaaprotocolforbayesiannetworkmetaanalysisandsystematicreview
AT songgeliang oraltraditionalchinesepatentmedicinescombinedwithnonsteroidalantiinflammatorydrugsforprimarydysmenorrheaaprotocolforbayesiannetworkmetaanalysisandsystematicreview
AT yangfengwen oraltraditionalchinesepatentmedicinescombinedwithnonsteroidalantiinflammatorydrugsforprimarydysmenorrheaaprotocolforbayesiannetworkmetaanalysisandsystematicreview
AT pangbo oraltraditionalchinesepatentmedicinescombinedwithnonsteroidalantiinflammatorydrugsforprimarydysmenorrheaaprotocolforbayesiannetworkmetaanalysisandsystematicreview
AT wanghui oraltraditionalchinesepatentmedicinescombinedwithnonsteroidalantiinflammatorydrugsforprimarydysmenorrheaaprotocolforbayesiannetworkmetaanalysisandsystematicreview